IS8288A - Hliðstæður qínazólíns sem tálmar týrósín kínasa vitaka - Google Patents
Hliðstæður qínazólíns sem tálmar týrósín kínasa vitakaInfo
- Publication number
- IS8288A IS8288A IS8288A IS8288A IS8288A IS 8288 A IS8288 A IS 8288A IS 8288 A IS8288 A IS 8288A IS 8288 A IS8288 A IS 8288A IS 8288 A IS8288 A IS 8288A
- Authority
- IS
- Iceland
- Prior art keywords
- tyrosine kinase
- inhibit tyrosine
- kinase kinases
- quinazoline analogues
- quinazoline
- Prior art date
Links
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Structural Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/642,440 US7501427B2 (en) | 2003-08-14 | 2003-08-14 | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US55171804P | 2004-03-10 | 2004-03-10 | |
| PCT/US2004/026235 WO2005016346A1 (en) | 2003-08-14 | 2004-08-10 | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8288A true IS8288A (is) | 2006-02-07 |
Family
ID=34198338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8288A IS8288A (is) | 2003-08-14 | 2006-02-07 | Hliðstæður qínazólíns sem tálmar týrósín kínasa vitaka |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7452895B2 (enExample) |
| EP (1) | EP1660090B1 (enExample) |
| JP (1) | JP4828421B2 (enExample) |
| KR (2) | KR101028952B1 (enExample) |
| CN (3) | CN103772373B (enExample) |
| AR (1) | AR045378A1 (enExample) |
| AU (1) | AU2004264937B2 (enExample) |
| BR (1) | BRPI0413565B8 (enExample) |
| CA (1) | CA2535614C (enExample) |
| CL (1) | CL2004002066A1 (enExample) |
| CY (1) | CY1113992T1 (enExample) |
| DK (1) | DK1660090T3 (enExample) |
| ES (1) | ES2399427T3 (enExample) |
| IL (1) | IL173593A (enExample) |
| IS (1) | IS8288A (enExample) |
| MX (1) | MXPA06001767A (enExample) |
| NO (1) | NO336275B1 (enExample) |
| NZ (1) | NZ545459A (enExample) |
| PL (1) | PL1660090T3 (enExample) |
| PT (1) | PT1660090E (enExample) |
| RU (1) | RU2350605C2 (enExample) |
| TW (1) | TWI353982B (enExample) |
| WO (1) | WO2005016346A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7488823B2 (en) * | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| JP4828421B2 (ja) * | 2003-08-14 | 2011-11-30 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
| DE602006021645D1 (de) | 2005-11-15 | 2011-06-09 | Array Biopharma Inc | Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten |
| KR102000312B1 (ko) | 2011-10-14 | 2019-07-15 | 어레이 바이오파마 인크. | Erb2 (her2) 저해제의 고체 분산물 |
| US9168254B2 (en) | 2011-10-14 | 2015-10-27 | Array Biopharma Inc. | Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them |
| RS57140B1 (sr) | 2012-03-23 | 2018-07-31 | Array Biopharma Inc | Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga |
| KR20180048804A (ko) | 2015-09-04 | 2018-05-10 | 아슬란 파마슈티컬스 피티이 엘티디 | 바리티닙 및 항암제를 포함하는 병용 요법 |
| WO2017184086A1 (en) * | 2016-04-21 | 2017-10-26 | Aslan Pharmaceuticals Pte. Ltd. | Method of treating liver cancer |
| GB201611580D0 (en) * | 2016-07-01 | 2016-08-17 | Aslan Pharmaceuticals Pte Ltd | Method |
| CN106317039A (zh) * | 2016-08-09 | 2017-01-11 | 浙江医药高等专科学校 | 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途 |
| CN106349230A (zh) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
| CN106279135A (zh) * | 2016-08-09 | 2017-01-04 | 浙江医药高等专科学校 | 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂 |
| CN106317040A (zh) * | 2016-08-09 | 2017-01-11 | 浙江医药高等专科学校 | 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途 |
| CN106349231A (zh) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂 |
| EP3504244A4 (en) | 2016-08-26 | 2020-08-19 | Agency for Science, Technology and Research | MACROPHAGE-STIMULATING PROTEIN RECEPTOR ANTIBODIES (OR OF NANTAIS ORIGINAL RON-RECEPTOR) AND THEIR USES |
| TW201834649A (zh) | 2017-03-02 | 2018-10-01 | 新加坡商亞獅康私人有限公司 | 癌症療法 |
| EP3615067A1 (en) | 2017-04-28 | 2020-03-04 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
| WO2018222134A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
| HRP20240293T1 (hr) | 2018-09-18 | 2024-05-24 | F. Hoffmann - La Roche Ag | Derivati kinazolina kao protutumorska sredstva |
| KR20210090625A (ko) * | 2018-10-09 | 2021-07-20 | 아슬란 파마슈티컬스 피티이 엘티디 | 바를리티닙의 말론산 염 |
| CR20210587A (es) | 2019-05-31 | 2022-02-11 | Janssen Pharmaceutica Nv | Inhibidores de molécula pequeña de quinasa inductora de nf-kb |
| CN111499622B (zh) * | 2019-07-08 | 2023-06-06 | 山东省科学院菏泽分院 | 一种治疗胆管癌的药物的制备方法 |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| EP4359082A1 (en) | 2021-06-26 | 2024-05-01 | Array BioPharma Inc. | Her2 mutation inhibitors |
| WO2023081637A1 (en) * | 2021-11-02 | 2023-05-11 | Enliven Therapeutics, Inc. | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 |
| US20250206760A1 (en) * | 2022-03-28 | 2025-06-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof |
| EP4786473A1 (en) * | 2023-09-27 | 2026-08-05 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt and crystalline form of quinazoline derivative, and use thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2583774A (en) | 1948-04-30 | 1952-01-29 | Merck & Co Inc | Vitamin b6 derivatives |
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US5204348A (en) * | 1988-10-06 | 1993-04-20 | Mitsui Toatsu Chemicals Inc. | Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components |
| CA1340821C (en) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (enExample) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| ATE446955T1 (de) * | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| SK6652000A3 (en) | 1997-11-11 | 2002-05-09 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| EP1066039A4 (en) | 1998-03-02 | 2003-02-26 | Cocensys Inc | SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES |
| US6017922A (en) | 1998-05-18 | 2000-01-25 | U.S. Bioscience, Inc. | Thermally stable trimetrexates and processes for producing the same |
| CN1160338C (zh) | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂 |
| ID30439A (id) | 1999-01-13 | 2001-12-06 | Warner Lambert Co | Benzoheterosiklus dan penggunaannya sebagai penghambat mek |
| EE05345B1 (et) * | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| HK1046688A1 (zh) | 1999-09-21 | 2003-01-24 | Astrazeneca Ab | 喹唑啉化合物和含有喹唑啉化合物的藥物組合物 |
| GB9922171D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| PL201790B1 (pl) | 2000-02-17 | 2009-05-29 | Bristol Myers Squibb Co | Anilinopochodny ligand dla receptora tarczycy, jego zastosowanie i kompozycja farmaceutyczna |
| BR0111377A (pt) | 2000-06-06 | 2003-06-03 | Pfizer Prod Inc | Derivados de tiofeno úteis como agentes anticancerìgenos |
| CN1437594A (zh) | 2000-06-22 | 2003-08-20 | 辉瑞产品公司 | 用于治疗异常细胞生长的取代的双环衍生物 |
| CA2413134C (en) * | 2000-06-30 | 2010-05-11 | Glaxo Group Limited | Quinazoline ditosylate salt compounds |
| US7265134B2 (en) | 2001-08-17 | 2007-09-04 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003037252A2 (en) | 2001-10-30 | 2003-05-08 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| RU2004116911A (ru) | 2001-11-03 | 2005-11-10 | Астразенека Аб (Se) | Производные хиназолина в качестве противоопухолевых средств |
| ATE446093T1 (de) * | 2001-12-24 | 2009-11-15 | Astrazeneca Ab | Substituierte chinazolin-derivate als aurora- kinase inhibitoren |
| US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| JP2006515871A (ja) | 2003-01-23 | 2006-06-08 | ティー．ケイ． シグナル リミテッド | 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用 |
| PE20040945A1 (es) | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| EP1636195A1 (en) | 2003-05-27 | 2006-03-22 | Pfizer Products Inc. | Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors |
| US7501427B2 (en) * | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| JP4828421B2 (ja) | 2003-08-14 | 2011-11-30 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
| SG135193A1 (en) | 2003-08-18 | 2007-09-28 | Pfizer Prod Inc | Dosing schedule for erbb2 anticancer agents |
| WO2005044302A1 (en) | 2003-11-06 | 2005-05-19 | Pfizer Products Inc. | Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| DE602006021645D1 (de) | 2005-11-15 | 2011-06-09 | Array Biopharma Inc | Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten |
-
2004
- 2004-08-10 JP JP2006523384A patent/JP4828421B2/ja not_active Expired - Lifetime
- 2004-08-10 NZ NZ545459A patent/NZ545459A/en not_active IP Right Cessation
- 2004-08-10 CA CA002535614A patent/CA2535614C/en not_active Expired - Lifetime
- 2004-08-10 BR BRPI0413565A patent/BRPI0413565B8/pt not_active IP Right Cessation
- 2004-08-10 PT PT47809900T patent/PT1660090E/pt unknown
- 2004-08-10 EP EP04780990A patent/EP1660090B1/en not_active Expired - Lifetime
- 2004-08-10 RU RU2006103493/04A patent/RU2350605C2/ru active
- 2004-08-10 AU AU2004264937A patent/AU2004264937B2/en active Active
- 2004-08-10 DK DK04780990.0T patent/DK1660090T3/da active
- 2004-08-10 ES ES04780990T patent/ES2399427T3/es not_active Expired - Lifetime
- 2004-08-10 MX MXPA06001767A patent/MXPA06001767A/es active IP Right Grant
- 2004-08-10 US US10/914,974 patent/US7452895B2/en not_active Expired - Lifetime
- 2004-08-10 WO PCT/US2004/026235 patent/WO2005016346A1/en not_active Ceased
- 2004-08-10 CN CN201310581100.3A patent/CN103772373B/zh not_active Expired - Lifetime
- 2004-08-10 KR KR1020107000942A patent/KR101028952B1/ko not_active Expired - Lifetime
- 2004-08-10 PL PL04780990T patent/PL1660090T3/pl unknown
- 2004-08-10 CN CN201110283526.1A patent/CN102432552B/zh not_active Expired - Lifetime
- 2004-08-10 CN CN201310428856.4A patent/CN103664802B/zh not_active Expired - Lifetime
- 2004-08-10 KR KR1020067003060A patent/KR100953246B1/ko not_active Expired - Lifetime
- 2004-08-13 TW TW093124336A patent/TWI353982B/zh not_active IP Right Cessation
- 2004-08-13 CL CL200402066A patent/CL2004002066A1/es unknown
- 2004-08-13 AR ARP040102929A patent/AR045378A1/es active IP Right Grant
-
2006
- 2006-02-07 IL IL173593A patent/IL173593A/en active IP Right Grant
- 2006-02-07 IS IS8288A patent/IS8288A/is unknown
- 2006-03-13 NO NO20061171A patent/NO336275B1/no unknown
-
2008
- 2008-10-10 US US12/249,421 patent/US8278314B2/en not_active Expired - Lifetime
-
2013
- 2013-02-08 CY CY20131100122T patent/CY1113992T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL174261A0 (en) | Quinazoline derivatives as tyrosine kinase inhibitors | |
| IL174258A0 (en) | Quinazoline derivatives as tyrosine kinase inhibitors | |
| IS7884A (is) | Díasepínóindól afleiður sem kínasa hindrar | |
| IS7328A (is) | Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum | |
| IL180806A0 (en) | Imidazopyrazine as tyrosine kinase inhibitors | |
| IL173593A0 (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
| IS6968A (is) | Nýir týrósínkínasa tálmar | |
| IS8077A (is) | Risahringa qínazólínafleiður sem miðlar gegn fjölgun | |
| IL173200A0 (en) | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors | |
| IS6886A (is) | Kínasólín sem MMP-13 hindrar | |
| MA28876B1 (fr) | Amides bicycliques comme inhibiteurs de kinases | |
| EP1581539A4 (en) | NEW TYROSINE KINASE HEMMER | |
| ATE505471T1 (de) | Azaindol-kinaseinhibitoren | |
| AU2003282891A8 (en) | Novel tyrosine kinases inhibitors | |
| IS7990A (is) | Amínóheteróarýl efnasambönd sem prótín kínasa hindrar | |
| NO20043162L (no) | Kinazolinforbindelser | |
| IL179081A0 (en) | QUINAZOLINE DERIVATIVES AS erbB RECEPTOR TYROSINE KINASES | |
| EP1534268A4 (en) | TYROSINE KINASE INHIBITORS | |
| EP1545529A4 (en) | NEW TYROSINE KINASE HEMMER | |
| IL187895A0 (en) | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | |
| IL184798A0 (en) | Quinazoline derivatives as tyrosine kinase inhibitors | |
| PL1854789T3 (pl) | Pochodna chinazoliny mająca aktywność hamowania kinazy tyrozynowej | |
| IS7849A (is) | Kínasólínafleiður sem SRC týrósínkínasatálmar | |
| SI1660090T1 (sl) | Kinazolinski analogi kot inhibitorji receptorjev tirozin kinaze | |
| EP1720542A4 (en) | ARYL ALKYLAMINO-SUBSTITUTED CHINAZOLINE ANALOGUE |